Aspira Women's Health Appoints New Directors, Adjusts Executive Pay
Ticker: AWHL · Form: 8-K · Filed: Feb 10, 2025 · CIK: 926617
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Aspira Women's Health adds 2 directors and updates CEO/CFO pay packages.
AI Summary
Aspira Women's Health Inc. announced on February 5, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David E.I. Enoch and Ms. Jennifer L. McNeely, to its Board of Directors, effective February 5, 2025. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Ms. R. Wendie Lachance, and Chief Financial Officer, Mr. David L. Clapper, detailing their compensation and severance packages.
Why It Matters
The appointment of new directors and adjustments to executive compensation can signal strategic shifts or changes in governance for Aspira Women's Health, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Dr. David E.I. Enoch (person) — Newly Elected Director
- Ms. Jennifer L. McNeely (person) — Newly Elected Director
- Ms. R. Wendie Lachance (person) — Chief Executive Officer
- Mr. David L. Clapper (person) — Chief Financial Officer
- February 5, 2025 (date) — Effective date of director appointments and event date
FAQ
Who were the new directors appointed to the Board of Directors?
Dr. David E.I. Enoch and Ms. Jennifer L. McNeely were elected to the Board of Directors.
When were the new directors' appointments effective?
The appointments of Dr. David E.I. Enoch and Ms. Jennifer L. McNeely were effective February 5, 2025.
Which executives entered into new employment agreements?
The company entered into new employment agreements with its Chief Executive Officer, Ms. R. Wendie Lachance, and Chief Financial Officer, Mr. David L. Clapper.
What is the filing date of this 8-K report?
This 8-K report was filed on February 10, 2025.
What was the former name of Aspira Women's Health Inc.?
Aspira Women's Health Inc. was formerly known as VERMILLION, INC. and CIPHERGEN BIOSYSTEMS INC.
Filing Stats: 614 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-02-10 17:00:35
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Stock Mark
Filing Documents
- form8-k.htm (8-K) — 45KB
- 0001493152-25-005666.txt ( ) — 217KB
- awh-20250205.xsd (EX-101.SCH) — 3KB
- awh-20250205_lab.xml (EX-101.LAB) — 33KB
- awh-20250205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aspira Women's Health Inc. Date: February 10, 2025 By: /s/ Mike Buhle Mike Buhle, CEO -3-